mRNA patent trial against BioNTech suspended by German court
Duesseldorf: A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European...
Login or Register to read the full article
Duesseldorf: A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.
The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European patent offices on a legal challenge filed by BioNTech.
A separate patent infringement case brought by CureVac was previously suspended by the Duesseldorf court because a higher court first needs to review that patent's validity. A decision is expected in December.
Read also: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd